Waubant E - Search Results

1

Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.

Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D. Mowry EM, et al. Among authors: waubant e. Ann Neurol. 2012 Aug;72(2):234-40. doi: 10.1002/ana.23591. Ann Neurol. 2012. PMID: 22926855 Free PMC article.

2

A serial study of new MS lesions and the white matter from which they arise.

Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. Goodkin DE, et al. Among authors: waubant e. Neurology. 1998 Dec;51(6):1689-97. doi: 10.1212/wnl.51.6.1689. Neurology. 1998. PMID: 9855524

3

[Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].

Waubant E, Sloan R, Andersson PB, Goodkin D. Waubant E, et al. Rev Neurol (Paris). 1999;155 Suppl 2:S20-3. Rev Neurol (Paris). 1999. PMID: 10367321 Clinical Trial. French.

4

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

Andersson PB, Waubant E, Gee L, Goodkin DE. Andersson PB, et al. Among authors: waubant e. Arch Neurol. 1999 Sep;56(9):1138-42. doi: 10.1001/archneur.56.9.1138. Arch Neurol. 1999. PMID: 10488816

5

A pilot study of MRI activity before and during interferon beta-1a therapy.

Waubant E, Goodkin DE, Sloan R, Andersson PB. Waubant E, et al. Neurology. 1999 Sep 11;53(4):874-6. doi: 10.1212/wnl.53.4.874. Neurology. 1999. PMID: 10489060

6

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.

Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K. Waubant E, et al. Neurology. 1999 Oct 22;53(7):1397-401. doi: 10.1212/wnl.53.7.1397. Neurology. 1999. PMID: 10534241

7

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.

Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. Goodkin DE, et al. Among authors: waubant e. Neurology. 2000 Apr 11;54(7):1414-20. doi: 10.1212/wnl.54.7.1414. Neurology. 2000. PMID: 10751249 Clinical Trial.

8

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.

Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S. Kita M, et al. Among authors: waubant e. Neurology. 2000 May 9;54(9):1741-5. doi: 10.1212/wnl.54.9.1741. Neurology. 2000. PMID: 10802778

9

1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW. Suhy J, et al. Among authors: waubant e. Mult Scler. 2000 Jun;6(3):148-55. doi: 10.1177/135245850000600303. Mult Scler. 2000. PMID: 10871825 Free PMC article.

10

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS.

Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, Goodkin D. Waubant E, et al. J Neuroimmunol. 2001 Jan 1;112(1-2):139-45. doi: 10.1016/s0165-5728(00)00355-6. J Neuroimmunol. 2001. PMID: 11108942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters